Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine relapse-prevention study in generalized anxiety disorder
ISRCTN38094599Phase 3Completed
- Sponsor
- Servier
- Start
- Oct 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Agomelatine continuation with Placebo (2 arms). Primary endpoint: Time to relapse. Started Oct 2007; status: completed.
02
Drugs
agomelatine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on ISRCTN38094599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38094599.